为您找到相关结果约20个

你是不是要搜索 期刊BETonMACE 点击跳转

for heart failure in patients following an acute coronary syndrome: a prespecified analysis of the BETonMACE

BET-inhibition with Apabetalone in Post-ACS Patients with Diabetes: Design and Baseline Characteristics of the BETonMACE

patients with acute coronary syndrome and diabetes: Rationale, design, and baseline characteristics of the BETonMACE

EVENTS IN PATIENTS WITH CHRONIC KIDNEY DISEASE, TYPE 2 DIABETES, AND RECENT ACUTE CORONARY SYNDROME: A BETONMACE

Apabetalone on Cardiovascular Outcomes in Patients With Acute Coronary Syndrome and Diabetes - Results of the BETonMACE

to the risk of major adverse cardiovascular events after acute coronary syndrome: an analysis of the BETonMACE

BET PROTEIN INHIBITION AND COGNITION: A PRE-SPECIFIED SUBSTUDY OF THE BETONMACE PHASE 3 TRIAL EVALUATING

A BETONMACE TRIAL REPORT

AND AN ELEVATED ANGULO NON-ALCOHOLIC FATTY LIVER DISEASE FIBROSIS SCORE - EXPLORATORY ANALYSIS OF THE BETONMACE

DESIGN FEATURES OF THE BETONMACE CHRONIC KIDNEY DISEASE SUB-STUDY; EFFECTS OF THE SELECTIVE BET-INHIBITOR

Recent Acute Coronary Syndrome and Type 2 Diabetes According to Insulin Treatment: Analysis of the Betonmace

How Might Bromodomain and Extra-Terminal (BET) Inhibitors Operate in Cardiovascular Disease?

Apabetalone (RVX-208) reduces vascular inflammation in vitro and in CVD patients by a BET-dependent epigenetic mechanism

Targeting epigenetics as atherosclerosis treatment: an updated view

Apabetalone Downregulates Fibrotic, Inflammatory and Calcific Processes in Renal Mesangial Cells and Patients with Renal Impairment

为您找到相关结果约20个

共20条页码: 1/2页15条/页